Skip Nav Destination
Issues
1 January 2010
-
Cover Image
Cover Image
The cover shows a tissue section from a murine model of skin basal cell carcinoma (BCC) related to aberrant hedgehog signaling (20X magnification; courtesy of Rehan Villani and Brandon Wainwright). The engineered mouse has a keratin 14 (K14) promoter-driven Cre recombinase transgene (K14-Cre) and a conditionally targeted allele of the Patched1 (Ptch1) gene (K14-Cre:Ptchllox/lox). The K14-Cre:Ptchllox/lox section shows immunofluorescence staining for proliferating cell nuclear antigen (PCNA; green), indicating proliferating cells of BCC, which are largely absent from stained sections of control littermates (Ptch1lox/lox; not shown). Staining also highlights K14 (red) in the basal cell population and DAPI counterstained nuclei (in all cell populations; blue). Epidermis-specific mutation of Ptch1 in the mice leads quickly to lesions closely resembling human BCC. Hedgehog signaling is constitutively activated (commonly via inactivated PTCH1) in human BCCs. Germline heterozygous mutations of PTCH1 highly predispose Gorlin syndrome patients to BCC with loss or inactivation of the remaining wild-type allele. See articles by Tang et al. (beginning on page 25 ), Rudin (beginning on page 1 ), and Arbiser (beginning on page 4 ) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspectives
Commentary
Research Articles
Basal Cell Carcinoma Chemoprevention with Nonsteroidal Anti-inflammatory Drugs in Genetically Predisposed PTCH1+/− Humans and Mice
Jean Y. Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A. Kohn; Charles E. McCulloch; Levy Kopelovich; David R. Bickers; Ervin H. Epstein, Jr.
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
Howard H. Bailey; KyungMann Kim; Ajit K. Verma; Karen Sielaff; Paul O. Larson; Stephen Snow; Theresa Lenaghan; Jaye L. Viner; Jeff Douglas; Nancy E. Dreckschmidt; Mary Hamielec; Marcy Pomplun; Harry H. Sharata; David Puchalsky; Eric R. Berg; Thomas C. Havighurst; Paul P. Carbone
Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA1 or BRCA2 Mutations
Alfonso Bellacosa; Andrew K. Godwin; Suraj Peri; Karthik Devarajan; Elena Caretti; Lisa Vanderveer; Betsy Bove; Carolyn Slater; Yan Zhou; Mary Daly; Sharon Howard; Kerry S. Campbell; Emmanuelle Nicolas; Anthony T. Yeung; Margie L. Clapper; James A. Crowell; Henry T. Lynch; Eric Ross; Levy Kopelovich; Alfred G. Knudson
Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence
Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S. Yang; Allan H. Conney
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.